Does Rallies show 13F holders for RXRX?

Yes. Rallies tracks hedge fund and 13F ownership data for RXRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is RXRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RXRX. It does not provide personalized investment advice.

RXRX (Recursion Pharmaceuticals, Inc. Class A Common Stock) Stock Analysis - Hedge Fund Holdings

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) is a publicly traded Healthcare sector company. As of May 21, 2026, RXRX trades at $2.95 with a market cap of $1.53B and a P/E ratio of -2.04. RXRX moved +4.04% today. Year to date, RXRX is -32.27%; over the trailing twelve months it is -34.95%. Its 52-week range spans $2.77 to $12.36. Analyst consensus is buy with an average price target of $7.38. Rallies surfaces RXRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RXRX stock?

Hedge funds tracked by Rallies that own RXRX include Nvidia Corp, Duquesne Family, Sculptor Capital, Pentwater Capital, and Pinebridge Investments. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Recursion Pharmaceuticals, Inc. Class A Common Stock.

RXRX Key Metrics

Key financial metrics for RXRX
Metric	Value
Price	$2.95
Market Cap	$1.53B
P/E Ratio	-2.04
EPS	$-1.44
Dividend Yield	0.00%
52-Week High	$12.36
52-Week Low	$2.77
Volume	12.10M
Avg Volume	0
Revenue (TTM)	$74.68M
Net Income	$-644.76M
Gross Margin	4.99%

Top Hedge Funds Holding RXRX

Nvidia Corp holds 7.71M shares of RXRX, changed +0.00% as of Sep 30, 2025.
Duquesne Family holds 906.77K shares of RXRX, changed +0.00% as of Dec 31, 2023.
Sculptor Capital holds 386.00K shares of RXRX, changed +966.30% as of Dec 31, 2025.
Pentwater Capital holds 100.00K shares of RXRX, changed +0.00% as of Dec 31, 2023.
Pinebridge Investments holds 26.14K shares of RXRX, changed +0.00% as of Sep 30, 2023.

Latest RXRX News

REC-1245 Shows No DLTs, 43% REC-4881 Polyp Reduction; $390M Burn Guidance — May 6, 2026
Recursion Appoints Vicki Goodman as CMO Effective April 6, Taps 20 Years Oncology Leadership — Mar 25, 2026
Recursion Pharmaceuticals Drops 11.8% Monthly; Q1 EPS Seen Improving 46% — Mar 10, 2026
Recursion Pharmaceuticals Posts $74.7M Revenue and Secures $134M Sanofi Milestone — Feb 26, 2026
Recursion Q4 Loss Narrows to $0.21, Revenue Hits $35.5M, Shares Jump 11% — Feb 25, 2026

Recent RXRX Insider Trades

Borgeson Blake sold 30.00K (~$105.60K) on May 5, 2026.
Gibson Christopher sold 40.00K (~$144.40K) on Apr 22, 2026.
Gibson Christopher sold 40.00K (~$124.00K) on Apr 7, 2026.

RXRX Analyst Consensus

5 analysts cover RXRX: 0 strong buy, 2 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.38.

Common questions about RXRX

Who owns RXRX stock?: Hedge funds tracked by Rallies that own RXRX include Nvidia Corp, Duquesne Family, Sculptor Capital, Pentwater Capital, and Pinebridge Investments. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Recursion Pharmaceuticals, Inc. Class A Common Stock.
Does Rallies show 13F holders for RXRX?: Yes. Rallies tracks hedge fund and 13F ownership data for RXRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RXRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RXRX. It does not provide personalized investment advice.